Impact of ranolazine on coronary microvascular dysfunction (MICRO) study

Area of Science:

• Cardiology
• Pharmacology

Background:

• Coronary microvascular dysfunction (CMVD) Type 1 lacks evidence-based treatments.
• Ranolazine shows potential for improving angina in Type 1 CMVD, but mechanisms are unclear.

Purpose of the Study:

• To assess ranolazine's impact on Type 1 CMVD using invasive microcirculatory resistance (IMR).

Main Methods:

• Seven patients with Type 1 CMVD received ranolazine 1000mg BID for four weeks.
• Coronary angiography and IMR were measured at baseline and post-treatment.
• Angina symptoms and activity levels were assessed using SAQ, DASI, and MET scores.

Main Results:

• Ranolazine significantly reduced mean IMR by 48% (p=0.02).
• Significant improvements were observed in physical limitation, angina frequency, angina stability, and disease perception (p<0.05).
• Activity scores showed non-significant improvements.

Conclusions:

• Pilot data suggest ranolazine favorably impacts IMR, angina symptoms, and activity in Type 1 CMVD.
• Further research in a larger cohort is warranted to confirm ranolazine's effects on microcirculatory function and angina.